litlas
Log inCreate account

John Stagg

Active 2004–2025

74
Papers
18,082
Citations
54
h-index
71
i10-index

Citations

Citations per year for John Stagg1992: 1 citations1996: 1 citations1999: 1 citations2005: 4 citations2006: 14 citations2007: 36 citations2008: 54 citations2009: 59 citations2010: 44 citations2011: 76 citations2012: 90 citations2013: 141 citations2014: 153 citations2015: 204 citations2016: 257 citations2017: 374 citations2018: 343 citations2019: 905 citations2020: 1,167 citations2021: 1,304 citations2022: 1,169 citations2023: 937 citations2024: 1,150 citations2025: 639 citations2026: 17 citations1993–1995: no citations, so these years are not shown1997–1998: no citations, so these years are not shown2000–2004: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,009 citing papers, 20.6% of this breakdownChina: 1,946 citing papers, 20% of this breakdownItaly: 501 citing papers, 5.1% of this breakdownGermany: 439 citing papers, 4.5% of this breakdownFrance: 400 citing papers, 4.1% of this breakdownUnited Kingdom: 387 citing papers, 4% of this breakdownCanada: 374 citing papers, 3.8% of this breakdownAustralia: 282 citing papers, 2.9% of this breakdownBelgium: 225 citing papers, 2.3% of this breakdownSpain: 215 citing papers, 2.2% of this breakdownJapan: 201 citing papers, 2.1% of this breakdownSouth Korea: 180 citing papers, 1.9% of this breakdown
0%20.6%Other 26.5%

Institutions

Fields

  • Medicine43%
  • Biochemistry, Genetics and Molecular Biology35.7%
  • Immunology and Microbiology15.3%
  • Engineering3.1%
  • Neuroscience0.8%
  • Materials Science0.6%
  • Other1.5%

Topics

  • Cancer Immunotherapy and Biomarkers10.5%
  • Immunotherapy and Immune Responses5.9%
  • Immune Cell Function and Interaction5.5%
  • Adenosine and Purinergic Signaling4.7%
  • Immune cells in cancer4.1%
  • CAR-T cell therapy research3.9%
  • Other65.4%

Coauthors

All papers

Open in search
  1. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

    Authors: Lukas F. Mager, Regula Burkhard, Nicola Pett, Noah C.A. Cooke, Kirsty Brown, Hena R. Ramay, Seungil Paik, John Stagg, Ryan A. Groves, Marco Gallo, Ian A. Lewis, Markus B. Geuking, Kathy D. McCoy - Science 2020 cited by 1,387

  2. Immune evasion in cancer: Mechanistic basis and therapeutic strategies

    Authors: Dass S. Vinay, Elizabeth P. Ryan, Graham Pawelec, Wamidh H. Talib, John Stagg, Eyad Elkord, Terry Lichtor, William K. Decker, Richard L. Whelan, H. M. C. Shantha Kumara, Emanuela Signori, Kanya Honoki, Alexandros G. Georgakilas, Amr Amin, William G. Helferich, Chandra S. Boosani, Gunjan Guha, Maria Rosa Ciriolo, Sophie Chen, Sulma I. Mohammed, Asfar S. Azmi, W. Nicol Keith, Alan Bilsland, Dipita Bhakta-Guha, Dorota Halicka, Hiromasa Fujii, Katia Aquilano, S. M. Ashraf, Somaira Nowsheen, Xujuan Yang, Beom K. Choi, Byoung S. Kwon - Seminars in Cancer Biology 2015 cited by 1,653

  3. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Authors: Lorenzo Galluzzi, Ilio Vitale, Sarah H. Warren, Sandy Adjemian, Patrizia Agostinis, Aitziber Buqué Martinez, Timothy A. Chan, George Coukos, Sandra Demaria, Éric Deutsch, Dobrin Draganov, Richard L. Edelson, Silvia C. Formenti, Jitka Fučíková, Lucia Gabriele, Udo S. Gaipl, Sofia R. Gameiro, Abhishek D. Garg, Encouse B. Golden, Jian Han, Kevin J. Harrington, Akseli Hemminki, James W. Hodge, Dewan Md Sakib Hossain, Tim Illidge, Michael Karin, Howard L. Kaufman, Oliver Kepp, Guido Kroemer, Juan José Lasarte, Sherene Loi, Michael T. Lotze, Gwenola Manic, Taha Merghoub, Alan Melcher, Karen Mossman, Felipe Prósper, Øystein Rekdal, María Rescigno, Chiara Riganti, Antonella Sistigu, Mark J. Smyth, Radek Špíšek, John Stagg, Bryan E. Strauss, Daolin Tang, Kazuki Tatsuno, Stefaan Van Gool, Peter Vandenabeele, Takahiro Yamazaki, Dmitriy Zamarin, Laurence Zitvogel, Alessandra Cesano, Francesco M. Marincola - Journal for ImmunoTherapy of Cancer 2020 cited by 1,061

  4. The adenosine pathway in immuno-oncology

    Authors: Bertrand Allard, David Allard, Laurence Buisseret, John Stagg - Nature Reviews Clinical Oncology 2020 cited by 565

  5. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

    Authors: Bertrand Allard, Maria Serena Longhi, Simon C. Robson, John Stagg - Immunological Reviews 2017 cited by 895

  6. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers

    Authors: Tina Gruosso, Mathieu Gigoux, Venkata Manem, Nicholas Bertos, Dongmei Zuo, Irina Perlitch, Sadiq M.I. Saleh, Hong Zhao, Margarita Souleimanova, Radia Marie Johnson, Anne Monette, Valentina Muñoz Ramos, Michael Hallett, John Stagg, Réjean Lapointe, Atilla Ömeroğlu, Sarkis Meterissian, Laurence Buisseret, Gert Van den Eyden, Roberto Salgado, Marie-Christine Guiot, Benjamin Haibe‐Kains, Morag Park - Journal of Clinical Investigation 2019 cited by 427

  7. Consensus guidelines for the detection of immunogenic cell death

    Authors: Oliver Kepp, Laura Senovilla, Ilio Vitale, Erika Vacchelli, Sandy Adjemian, Patrizia Agostinis, Lionel Apétoh, Fernando Aranda, Vincenzo Barnaba, Norma Bloy, Laura Bracci, Karine Breckpot, David Brough, Aitziber Buqué, María G. Castro, Mara Cirone, María I. Colombo, Isabelle Cremer, Sandra Demaria, Luciana Dini, Aristides G. Eliopoulos, Alberto Faggioni, Silvia C. Formenti, Jitka Fučíková, Lucia Gabriele, Udo S. Gaipl, Jérôme Galon, Abhishek D. Garg, François Ghiringhelli, Nathalia A. Giese, Zong Sheng Guo, Akseli Hemminki, Martin Herrmann, James W. Hodge, Stefan Holdenrieder, Jamie Honeychurch, Hong‐Ming Hu, Xing Huang, Tim Illidge, Koji Kono, Mladen Korbelik, Dmitri V. Krysko, Sherene Loi, Pedro R. Löwenstein, Enrico Lugli, Yuting Ma, Frank Madeo, Angelo A. Manfredi, Isabelle Martins, Domenico Mavilio, Laurie Menger, Nicolò Merendino, Michael Michaud, Grégoire Mignot, Karen Mossman, Gabriele Multhoff, Rudolf Oehler, Fabio Palombo, Theocharis Panaretakis, Jonathan Pol, Enrico Proietti, Jean‐Ehrland Ricci, Chiara Riganti, Patrizia Rovere–Querini, Anna Rubartelli, Antonella Sistigu, Mark J. Smyth, Juergen Sonnemann, Radek Špíšek, John Stagg, Abdul Qader Sukkurwala, Éric Tartour, Andrew Thorburn, Stephen H. Thorne, Peter Vandenabeele, Francesca Velotti, Samuel T. Workenhe, Haining Yang, Wei‐Xing Zong, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi - OncoImmunology 2014 cited by 824

  8. Spatially mapping the immune landscape of melanoma using imaging mass cytometry

    Authors: Dan Moldoveanu, LeeAnn Ramsay, Mathieu Lajoie, Luke Anderson-Trocmé, Marine Lingrand, Diana Berry, Lucas J. M. Perus, Yuhong Wei, Cleber Moraes, Rached Alkallas, Shivshankari Rajkumar, Dongmei Zuo, Matthew Dankner, Eric Hongbo Xu, Nicholas Bertos, Hamed S. Najafabadi, Simon Gravel, Santiago Costantino, Martin J. Richer, Amanda W. Lund, Sonia V. del Rincón, Alan Spatz, Wilson H. Miller, Rahima Jamal, Réjean Lapointe, Anne‐Marie Mes‐Masson, Simon Turcotte, Kevin Petrecca, Sinziana Dumitra, Ari N. Meguerditchian, Keith Richardson, Francine Tremblay, Béatrice Wang, May Chergui, Marie‐Christine Guiot, Kevin Watters, John Stagg, Daniela F. Quail, Catalin Mihalcioiu, Sarkis Meterissian, Ian R. Watson - Science Immunology 2022 cited by 131

  9. Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

    Authors: Abhishek D. Garg, Lorenzo Galluzzi, Lionel Apétoh, Thaïs Baert, Raymond B. Birge, José Manuel Bravo‐San Pedro, Karine Breckpot, David Brough, Ricardo A. Chaurio, Mara Cirone, An Coosemans, Pierre G. Coulie, Dirk De Ruysscher, Luciana Dini, Peter de Witte, Aleksandra M. Dudek-Perić, Alberto Faggioni, Jitka Fučíková, Udo S. Gaipl, Jakub Gołąb, Marie-Lise Gougeon, Michael R. Hamblin, Akseli Hemminki, Martin Herrmann, James W. Hodge, Oliver Kepp, Guido Kroemer, Dmitri V. Krysko, W. Land, Frank Madeo, Angelo A. Manfredi, Stephen R. Mattarollo, Christian Maueröder, Nicolò Merendino, Gabriele Multhoff, Thomas Pabst, Jean‐Ehrland Ricci, Chiara Riganti, Erminia Romano, Nicole Rufo, Mark J. Smyth, Jürgen Sonnemann, Radek Špíšek, John Stagg, Erika Vacchelli, Peter Vandenabeele, Lien Vandenberk, Benoı̂t J. Van den Eynde, Stefaan Van Gool, Francesca Velotti, Laurence Zitvogel, Patrizia Agostinis - Frontiers in Immunology 2015 cited by 396

  10. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach

    Authors: Yacine Barèche, Laurence Buisseret, Tina Gruosso, Edwina Girard, David Venet, Floriane Dupont, Christine Desmedt, Denis Larsimont, Morag Park, Françoise Rothé, John Stagg, Christos Sotiriou - JNCI Journal of the National Cancer Institute 2019 cited by 204

  11. Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

    Authors: Bertrand Allard, Sandra Pommey, Mark J. Smyth, John Stagg - Clinical Cancer Research 2013 cited by 451

  12. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

    Authors: Paul A. Beavis, Melissa A. Henderson, Lauren Giuffrida, Jane K. Mills, Kevin Sek, Ryan Cross, Alexander J. Davenport, Liza B. John, Sherly Mardiana, Clare Y. Slaney, Ricky W. Johnstone, Joseph A. Trapani, John Stagg, Sherene Loi, Lev M. Kats, David Gyorki, Michael H. Kershaw, Phillip K. Darcy - Journal of Clinical Investigation 2017 cited by 321

  13. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

    Authors: Paul A. Beavis, Nicole Milenkovski, Melissa A. Henderson, Liza B. John, Bertrand Allard, Sherene Loi, Michael H. Kershaw, John Stagg, Phillip K. Darcy - Cancer Immunology Research 2015 cited by 329

  14. Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy

    Authors: John Stagg, Sherene Loi, Upulie Divisekera, Shin Foong Ngiow, Helene Duret, Hideo Yagita∥, Michele W.L. Teng, Mark J. Smyth - National Academy of Sciences, Proceedings of the National Academy of Sciences 2011 cited by 487

  15. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer

    Authors: Laurence Buisseret, Soizic Garaud, Alexandre de Wind, Gert Van den Eynden, Anaïs Boisson, Cinzia Solinas, Chunyan Gu‐Trantien, Céline Naveaux, Jean‐Nicolas Lodewyckx, Hugues Duvillier, Ligia Craciun, Isabelle Veys, Denis Larsimont, Martine Piccart, John Stagg, Christos Sotiriou, Karen Willard‐Gallo - OncoImmunology 2016 cited by 236

  16. Leveraging big data of immune checkpoint blockade response identifies novel potential targets

    Authors: Yacine Barèche, Deirdre Kelly, Farnoosh Abbas‐Aghababazadeh, Masahiro Nakano, Parinaz Nasr Esfahani, Douglas Tkachuk, Helai P. Mohammad, Robert Samstein, Chung‐Han Lee, Luc G.T. Morris, Philippe L. Bédard, Benjamin Haibe‐Kains, John Stagg - Annals of Oncology 2022 cited by 81

  17. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy

    Authors: John Stagg, Encouse B. Golden, Erik Wennerberg, Sandra Demaria - Science Immunology 2023 cited by 46

  18. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

    Authors: Sherene Loi, Sandra Pommey, Benjamin Haibe‐Kains, Paul A. Beavis, Phillip K. Darcy, Mark J. Smyth, John Stagg - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 490

  19. CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer

    Authors: Célia Jacoberger-Foissac, Isabelle Cousineau, Yacine Barèche, David Allard, Pavel Chrobák, Bertrand Allard, Sandra Pommey, Nouredin Messaoudi, Yannic McNicoll, Geneviève Soucy, Secil Koseoglu, Ricard Masia, Andrew C. Lake, Heewon Seo, Christopher Eeles, Neha Rohatgi, Simon C. Robson, Simon Turcotte, Benjamin Haibe‐Kains, John Stagg - Cancer Immunology Research 2022 cited by 73

  20. CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer

    Authors: Martin Turcotte, Kathleen Spring, Sandra Pommey, Guillaume Chouinard, Isabelle Cousineau, Joshy George, Gregory M. Chen, Deena M.A. Gendoo, Benjamin Haibe‐Kains, Thomas Karn, Kurosh Rahimi, Cécile Le Page, Diane Provencher, Anne‐Marie Mes‐Masson, John Stagg - Cancer Research 2015 cited by 260

  21. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

    Authors: Laurence Buisseret, Sandra Pommey, Bertrand Allard, Soizic Garaud, M. Bergeron, Isabelle Cousineau, Lieveke Ameye, Yacine Barèche, Marianne Paesmans, John Crown, Angelo Di Leo, Sherene Loi, Martine Piccart, Karen Willard‐Gallo, Christos Sotiriou, John Stagg - Annals of Oncology 2017 cited by 240

  22. DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells

    Authors: Helen Loo Yau, Emma Bell, Ilias Ettayebi, Felipe Campos de Almeida, Giselle M. Boukhaled, Shu Yi Shen, David Allard, Beatriz Morancho, Sajid A. Marhon, Charles A. Ishak, Isabela M. Gonzaga, Tiago da Silva Medina, Rajat Singhania, Ankur Chakravarthy, Raymond Chen, Parinaz Mehdipour, Sandra Pommey, Christian Klein, Gustavo P. Amarante‐Mendes, David Roulois, Joaquı́n Arribas, John Stagg, David G. Brooks, Daniel D. De Carvalho - Molecular Cell 2021 cited by 87

  23. Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors

    Authors: Paul A. Beavis, Upulie Divisekera, Christophe Paget, Melvyn T. Chow, Liza B. John, Christel Devaud, Karen M. Dwyer, John Stagg, Mark J. Smyth, Phillip K. Darcy - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 343

  24. Immunosuppressive activities of adenosine in cancer

    Authors: Bertrand Allard, Paul A. Beavis, Phillip K. Darcy, John Stagg - Current Opinion in Pharmacology 2016 cited by 277